Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 147

1.

The prognostic role of blood lymphocyte subset distribution in patients with resected high-risk primary or regionally metastatic melanoma.

Hernberg M, Mattila PS, Rissanen M, Hansson J, Aamdal S, Bastholt L, von der Maase H, Schmidt H, Stierner U, Tarkkanen J.

J Immunother. 2007 Oct;30(7):773-9.

PMID:
17893569
[PubMed - indexed for MEDLINE]
2.

The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma.

Hernberg MM, Hahka-Kemppinen MH, Pyrhönen SO.

Melanoma Res. 2004 Dec;14(6):493-500.

PMID:
15577320
[PubMed - indexed for MEDLINE]
3.

Changes in the number of CD80(+), CD86(+), and CD28(+) peripheral blood lymphocytes have prognostic value in melanoma patients.

Martínez-Escribano JA, Hernández-Caselles T, Campillo JA, Campos M, Frías JF, García-Alonso A, Alvarez-López MR.

Hum Immunol. 2003 Aug;64(8):796-801.

PMID:
12878358
[PubMed - indexed for MEDLINE]
4.

Lymphocyte subpopulations and interleukin levels in high-risk melanoma patients treated with high-dose interferon A-2B.

Gogas H, Paterakis G, Frangia K, Bafaloukos D, Pectasides D, Kalofonos HP, Loukopoulos D, Stavropoulou-Giokas C, Ioannovich J, Mihm MC Jr.

Am J Clin Oncol. 2002 Dec;25(6):591-6.

PMID:
12478006
[PubMed - indexed for MEDLINE]
5.

Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.

Moschos SJ, Edington HD, Land SR, Rao UN, Jukic D, Shipe-Spotloe J, Kirkwood JM.

J Clin Oncol. 2006 Jul 1;24(19):3164-71.

PMID:
16809739
[PubMed - indexed for MEDLINE]
Free Article
6.

CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma.

Konjević G, Jović V, Vuletić A, Radulović S, Jelić S, Spuzić I.

Eur J Clin Invest. 2007 Nov;37(11):887-96.

PMID:
17973783
[PubMed - indexed for MEDLINE]
7.

Tumor-infiltrating lymphocytes in patients with metastatic melanoma receiving chemoimmunotherapy.

Hernberg M, Turunen JP, Muhonen T, Pyrhönen S.

J Immunother. 1997 Nov;20(6):488-95.

PMID:
9409455
[PubMed - indexed for MEDLINE]
8.

The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase.

Piras F, Colombari R, Minerba L, Murtas D, Floris C, Maxia C, Corbu A, Perra MT, Sirigu P.

Cancer. 2005 Sep 15;104(6):1246-54.

PMID:
16078259
[PubMed - indexed for MEDLINE]
Free Article
9.

Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.

Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, von der Maase H, Eggermont AM, Keilholz U; American Joint Committee on Cancer Stage IV Melanoma; EORTC 18951.

J Clin Oncol. 2007 Apr 20;25(12):1562-9.

PMID:
17443000
[PubMed - indexed for MEDLINE]
Free Article
10.

Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.

Bouwhuis MG, Suciu S, Collette S, Aamdal S, Kruit WH, Bastholt L, Stierner U, Salès F, Patel P, Punt CJ, Hernberg M, Spatz A, ten Hagen TL, Hansson J, Eggermont AM; EORTC Melanoma Group and the Nordic Melanoma Group.

J Natl Cancer Inst. 2009 Jun 16;101(12):869-77. doi: 10.1093/jnci/djp132. Epub 2009 Jun 9.

PMID:
19509353
[PubMed - indexed for MEDLINE]
Free Article
11.

The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy.

Hernberg M, Muhonen T, Turunen JP, Hahka-Kemppinen M, Pyrhönen S.

J Clin Oncol. 1996 May;14(5):1690-6.

PMID:
8622089
[PubMed - indexed for MEDLINE]
Free Article
12.

Aflatoxin B1 albumin adduct levels and cellular immune status in Ghanaians.

Jiang Y, Jolly PE, Ellis WO, Wang JS, Phillips TD, Williams JH.

Int Immunol. 2005 Jun;17(6):807-14. Epub 2005 Jun 8.

PMID:
15944194
[PubMed - indexed for MEDLINE]
Free Article
13.

Tumour-associated macrophages are related to progression in patients with metastatic melanoma following interleukin-2 based immunotherapy.

Hansen BD, Schmidt H, von der Maase H, Sjoegren P, Agger R, Hokland M.

Acta Oncol. 2006;45(4):400-5.

PMID:
16760175
[PubMed - indexed for MEDLINE]
14.

Serum LD1 isoenzyme and blood lymphocyte subsets as prognostic indicators for severe acute respiratory syndrome.

Chan MH, Wong VW, Wong CK, Chan PK, Chu CM, Hui DS, Suen MW, Sung JJ, Chung SS, Lam CW.

J Intern Med. 2004 Apr;255(4):512-8.

PMID:
15049886
[PubMed - indexed for MEDLINE]
15.

Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial.

Hersey P, Coates AS, McCarthy WH, Thompson JF, Sillar RW, McLeod R, Gill PG, Coventry BJ, McMullen A, Dillon H, Simes RJ.

J Clin Oncol. 2002 Oct 15;20(20):4181-90.

PMID:
12377961
[PubMed - indexed for MEDLINE]
Free Article
16.

Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.

Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H.

Cancer. 2006 Mar 1;106(5):1130-9. Erratum in: Cancer. 2006;107(9 No 1):2315.

PMID:
16456816
[PubMed - indexed for MEDLINE]
Free Article
17.

IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC.

Konjević G, Jović V, Jurisić V, Radulović S, Jelić S, Spuzić I.

Clin Exp Metastasis. 2003;20(7):647-55.

PMID:
14669796
[PubMed - indexed for MEDLINE]
18.

CD4(+)CD45RA(+)CXCR4 (+) lymphocytes are inversely associated with progression in stages I-III melanoma patients.

Napolitano M, Ottaiano A, Mauro F, Ieranò C, Satriano R, Pacelli R, Franco R, De Angelis V, Castello G, Scala S.

Cancer Immunol Immunother. 2010 Apr;59(4):511-7. doi: 10.1007/s00262-009-0766-8. Epub 2009 Sep 25.

PMID:
19779716
[PubMed - indexed for MEDLINE]
19.

Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.

Kirkwood JM, Richards T, Zarour HM, Sosman J, Ernstoff M, Whiteside TL, Ibrahim J, Blum R, Wieand S, Mascari R.

Cancer. 2002 Sep 1;95(5):1101-12.

PMID:
12209697
[PubMed - indexed for MEDLINE]
Free Article
20.

Detection of circulating tumor lysate-reactive CD4+ T cells in melanoma patients.

Ladekarl M, Agger R, Fleischer CC, Hokland M, Hulgaard EF, Kirkin A, von der Maase H, Petersen MS, Rytter C, Zeuthen J, Gundersen HJ.

Cancer Immunol Immunother. 2004 Jun;53(6):560-6. Epub 2004 Feb 25.

PMID:
14985861
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk